Icon

HYGROTON (nda012283)- (25MG,50MG)

CHLORTHALIDONE SANOFI AVENTIS US
25MG,50MG
No No
Expired Expired
None None
None No
HYGROTON is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.
17 0 16
Total Other Developers 1
Drugs with Suitability No
25MG ** ** - 15 -
50MG ** ** - 15 -
NDA Sales Available Total Generic Sales Available
No 16
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** ***** ********** ******** ********, *** *********** **** ******** ******, ************, ************ (**) *****, ****** ****** (***) ***
****** ****** **** ******* *************** **, *** *********** *** *** ***** ****, *********, *** ****** (**) *****, ****** ****** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ***** ***** ****** *** *********** *** *** *** ********* ** ***** *, *, *-* & *, **********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ******** ******** ********** ******* *********** **-**/*-***/*, ********** ********* ************* (****),, *****, *********** ******, ***** (***) ***
****** ******** ******** ******* *************** ***. *********** *** ***** *****, *********, ******** (**) *****, ****** ****** (***) ***
****** ************* ********** - ***?***** ******?*****, *.*. *********** *** ** *****, *******, ****-***, ******** (***) ***
****** ***** **** *** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** **** **. *-*** /* ***** *** - **** **, *******, ******* ******, ***** (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***
****** ******* ******* ************ ******* ******* *********** **** **. *** *** ***/*, ****, **** *****,, ****, ******* ******, ***** (***) ***
****** ******* ****** *************** ***. *********** ***** ****, *********, *******, ***** ****, ********** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ************* ********** - ***?***** ******?*****, *.*. *********** *** ** *****, *******, ****-***, ******** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.